| 001 | 276333 | ||
| 005 | 20240229155000.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ijrobp.2023.05.035 |2 doi |
| 024 | 7 | _ | |a pmid:37244626 |2 pmid |
| 024 | 7 | _ | |a 0360-3016 |2 ISSN |
| 024 | 7 | _ | |a 1879-355X |2 ISSN |
| 024 | 7 | _ | |a altmetric:149528439 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-01063 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Forster, Tobias |b 0 |
| 245 | _ | _ | |a Non-inferiority of local control and comparable toxicity of intensity-modulated radiotherapy with simultaneous integrated boost in breast cancer: 5-year results of the IMRT-MC2 phase III trial: IMRT-SIB is non-inferior to 3-D-CRT-seqB in RT for BC patients. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2023 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1698406219_6648 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Nov 15;117(4):857-868 / #LA:E050# |
| 520 | _ | _ | |a The IMRT-MC2 trial was conducted to demonstrate non-inferiority of conventionally fractionated intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) to 3-D-conformal radiotherapy with sequential boost (3-D-CRT-seqB) for adjuvant breast radiotherapy.A total of 502 patients were randomized between 2011 and 2015 for the prospective, multicenter, phase-III-trial (NCT01322854). 5-year results of late toxicity (LENT-SOMA), overall survival, disease-free survival, distant disease-free survival, cosmesis (Harvard scale) and local control (non-inferiority margin at hazard ratio of 3.5) were analyzed after a median follow-up of 62 months.The 5-year LC rate for the IMRT-SIB arm was non-inferior to the control arm (98.7% vs. 98.3%, respectively; HR 0.582, 95%-CI: [0.119-2.375], p=0.4595). Furthermore, there was no significant difference in overall survival (97.1% versus 98.3%, respectively; HR 1.235, 95%-CI: [0.472-3.413], p=0.6697), disease-free survival (95.8% versus 96.1%, respectively; HR 1.130, 95%-CI: [0.487-2.679], p=0.7758) and distant disease-free survival (97.0% versus 97.8%, respectively; HR 1.667, 95%-CI: [0.575-5.434], p=0.3601). After 5 years, late toxicity evaluation and cosmetic assessment further showed no significant differences between treatment arms.The 5-year results of the IMRT-MC2 trial provide strong evidence, that the application of conventionally fractionated simultaneous integrated boost irradiation for breast cancer patients is both safe and effective with non-inferior local control compared to 3-D-conformal radiotherapy with sequential boost. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a 3-D-conformal radiotherapy |2 Other |
| 650 | _ | 7 | |a 5-year follow-up |2 Other |
| 650 | _ | 7 | |a Breast cancer |2 Other |
| 650 | _ | 7 | |a intensity-modulated radiotherapy (IMRT) |2 Other |
| 650 | _ | 7 | |a local control |2 Other |
| 650 | _ | 7 | |a overall survival |2 Other |
| 650 | _ | 7 | |a sequential boost irradiation |2 Other |
| 650 | _ | 7 | |a simultaneously integrated boost (SIB) |2 Other |
| 700 | 1 | _ | |a Köhler, Clara |b 1 |
| 700 | 1 | _ | |a Dorn, Melissa |b 2 |
| 700 | 1 | _ | |a Häfner, Matthias Felix |b 3 |
| 700 | 1 | _ | |a Arians, Nathalie |b 4 |
| 700 | 1 | _ | |a König, Laila |b 5 |
| 700 | 1 | _ | |a Harrabi, Semi Ben |b 6 |
| 700 | 1 | _ | |a Schlampp, Ingmar |b 7 |
| 700 | 1 | _ | |a Weykamp, Fabian |b 8 |
| 700 | 1 | _ | |a Meixner, Eva |b 9 |
| 700 | 1 | _ | |a Lang, Kristin |b 10 |
| 700 | 1 | _ | |a Heinrich, Vanessa |b 11 |
| 700 | 1 | _ | |a Weidner, Nicola |b 12 |
| 700 | 1 | _ | |a Hüsing, Johannes |b 13 |
| 700 | 1 | _ | |a Wallwiener, Markus |b 14 |
| 700 | 1 | _ | |a Golatta, Michael |b 15 |
| 700 | 1 | _ | |a Hennigs, André |b 16 |
| 700 | 1 | _ | |a Heil, Jörg |b 17 |
| 700 | 1 | _ | |a Hof, Holger |b 18 |
| 700 | 1 | _ | |a Krug, David |b 19 |
| 700 | 1 | _ | |a Debus, Jürgen |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 20 |u dkfz |
| 700 | 1 | _ | |a Hörner-Rieber, Juliane |0 P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0 |b 21 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.ijrobp.2023.05.035 |g p. S0360301623005230 |0 PERI:(DE-600)1500486-7 |n 4 |p 857-868 |t International journal of radiation oncology, biology, physics |v 117 |y 2023 |x 0360-3016 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:276333 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-17 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-17 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-08-24 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-24 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J RADIAT ONCOL : 2022 |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-24 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J RADIAT ONCOL : 2022 |d 2023-08-24 |
| 920 | 2 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::